714 related articles for article (PubMed ID: 18156458)
1. Altered fibrin clot properties in patients on long-term haemodialysis: relation to cardiovascular mortality.
Undas A; Kolarz M; Kopeć G; Tracz W
Nephrol Dial Transplant; 2008 Jun; 23(6):2010-5. PubMed ID: 18156458
[TBL] [Abstract][Full Text] [Related]
2. Unfavorably altered fibrin clot properties in patients with active rheumatoid arthritis.
Kwasny-Krochin B; Gluszko P; Undas A
Thromb Res; 2010 Jul; 126(1):e11-6. PubMed ID: 20471669
[TBL] [Abstract][Full Text] [Related]
3. Fibrin clot structure in patients with end-stage renal disease.
Sjøland JA; Sidelmann JJ; Brabrand M; Pedersen RS; Pedersen JH; Esbensen K; Standeven KF; Ariëns RA; Gram J
Thromb Haemost; 2007 Aug; 98(2):339-45. PubMed ID: 17721616
[TBL] [Abstract][Full Text] [Related]
4. Plasma homocysteine affects fibrin clot permeability and resistance to lysis in human subjects.
Undas A; Brozek J; Jankowski M; Siudak Z; Szczeklik A; Jakubowski H
Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1397-404. PubMed ID: 16574890
[TBL] [Abstract][Full Text] [Related]
5. Fibrin clot properties are altered in patients with chronic obstructive pulmonary disease. Beneficial effects of simvastatin treatment.
Undas A; Kaczmarek P; Sladek K; Stepien E; Skucha W; Rzeszutko M; Gorkiewicz-Kot I; Tracz W
Thromb Haemost; 2009 Dec; 102(6):1176-82. PubMed ID: 19967149
[TBL] [Abstract][Full Text] [Related]
6. The effect of chronic kidney disease on fibrin clot properties in patients with acute coronary syndrome.
Undas A; Nycz K; Pastuszczak M; Stompor T; Zmudka K
Blood Coagul Fibrinolysis; 2010 Sep; 21(6):522-7. PubMed ID: 20479639
[TBL] [Abstract][Full Text] [Related]
7. Chronic inflammation and mortality in haemodialysis: effect of different renal replacement therapies. Results from the RISCAVID study.
Panichi V; Rizza GM; Paoletti S; Bigazzi R; Aloisi M; Barsotti G; Rindi P; Donati G; Antonelli A; Panicucci E; Tripepi G; Tetta C; Palla R;
Nephrol Dial Transplant; 2008 Jul; 23(7):2337-43. PubMed ID: 18305316
[TBL] [Abstract][Full Text] [Related]
8. Factor XIII Val34Leu polymorphism as a modulator of fibrin clot permeability and resistance to lysis in patients with severe coronary artery disease.
Stepień E; Plicner D; Kapelak B; Wypasek E; Sadowski J; Undas A
Kardiol Pol; 2009 Aug; 67(8A):947-55. PubMed ID: 19784898
[TBL] [Abstract][Full Text] [Related]
9. Inflammation, infection and cardiovascular events in chronic hemodialysis patients: a prospective study.
Bellomo G; Lippi G; Saronio P; Reboldi G; Verdura C; Timio F; Timio M
J Nephrol; 2003; 16(2):245-51. PubMed ID: 12768072
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the pro-thrombotic state in CAPD patients.
Preloznik Zupan I; Sabovic M; Salobir B; Buturovic Ponikvar J
Ren Fail; 2008; 30(6):597-602. PubMed ID: 18661409
[TBL] [Abstract][Full Text] [Related]
11. No-reflow phenomenon after acute myocardial infarction is associated with reduced clot permeability and susceptibility to lysis.
Zalewski J; Undas A; Godlewski J; Stepien E; Zmudka K
Arterioscler Thromb Vasc Biol; 2007 Oct; 27(10):2258-65. PubMed ID: 17673704
[TBL] [Abstract][Full Text] [Related]
12. Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress.
Undas A; Szułdrzynski K; Stepien E; Zalewski J; Godlewski J; Tracz W; Pasowicz M; Zmudka K
Atherosclerosis; 2008 Feb; 196(2):551-7. PubMed ID: 17640649
[TBL] [Abstract][Full Text] [Related]
13. The Diamant Alpin Dialysis cohort study: clinico-biological characteristics and cardiovascular genetic risk profile of incident patients.
Pernod G; Bosson JL; Golshayan D; Barro C; Alloatti S; Turc-Baron C; Quarello F; Jeantet A; Von Albertini B; Forêt M; Lauren G; Cordonnier D; Piccoli G; Wauters JP;
J Nephrol; 2004; 17(1):66-75. PubMed ID: 15151261
[TBL] [Abstract][Full Text] [Related]
14. Validity of plasma fibrinogen, D-dimer, and the von Willebrand factor as markers of cardiovascular morbidity in patients on chronic hemodialysis.
Kirmizis D; Tsiandoulas A; Pangalou M; Koutoupa E; Rozi P; Protopappa M; Barboutis K
Med Sci Monit; 2006 Feb; 12(2):CR55-62. PubMed ID: 16449948
[TBL] [Abstract][Full Text] [Related]
15. End-stage renal disease patients on renal replacement therapy in the intensive care unit: short- and long-term outcome.
Bell M; Granath F; Schön S; Löfberg E; ; Ekbom A; Martling CR
Crit Care Med; 2008 Oct; 36(10):2773-8. PubMed ID: 18766088
[TBL] [Abstract][Full Text] [Related]
16. Altered fibrin clot structure and function in the healthy first-degree relatives of subjects with intermittent claudication.
Bhasin N; Ariëns RA; West RM; Parry DJ; Grant PJ; Scott DJ
J Vasc Surg; 2008 Dec; 48(6):1497-503, 1503.e1. PubMed ID: 18829228
[TBL] [Abstract][Full Text] [Related]
17. Abnormal plasma fibrin clot characteristics are associated with worse clinical outcome in patients with peripheral arterial disease and thromboangiitis obliterans.
Undas A; Nowakowski T; Cieśla-Dul M; Sadowski J
Atherosclerosis; 2011 Apr; 215(2):481-6. PubMed ID: 21324459
[TBL] [Abstract][Full Text] [Related]
18. Soluble CD40 ligand is predictive of combined cardiovascular morbidity and mortality in patients on haemodialysis at a relatively short-term follow-up.
Desideri G; Panichi V; Paoletti S; Grassi D; Bigazzi R; Beati S; Bernabini G; Rosati A; Ferri C; Taddei S; Ghiadoni L;
Nephrol Dial Transplant; 2011 Sep; 26(9):2983-8. PubMed ID: 21303961
[TBL] [Abstract][Full Text] [Related]
19. Predictors of mortality in long-term haemodialysis patients with a low prevalence of comorbid conditions.
De Lima JJ; Sesso R; Abensur H; Lopes HF; Giorgi MC; Krieger EM; Pileggi F
Nephrol Dial Transplant; 1995; 10(9):1708-13. PubMed ID: 8559493
[TBL] [Abstract][Full Text] [Related]
20. Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis.
Konieczynska M; Fil K; Bazanek M; Undas A
Thromb Haemost; 2014 Apr; 111(4):685-93. PubMed ID: 24306139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
